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A B S T R A C T
Purpose
We investigated the effect on outcome of measurable or minimal residual disease (MRD) status
after each induction course to evaluate the extent of its predictive value for acute myeloid leukemia
(AML) risk groups, including NPM1 wild-type (wt) standard risk, when incorporated with other
induction response criteria.
Methods
As part of the NCRI AML17 trial, 2,450 younger adult patients with AML or high-risk myelodysplastic
syndrome had prospective multiparameter flow cytometric MRD (MFC-MRD) assessment. After
course 1 (C1), responses were categorized as resistant disease (RD), partial remission (PR), and
complete remission (CR) or complete remission with absolute neutrophil count , 1,000/mL or
thrombocytopenia , 100,000/mL (CRi) by clinicians, with CR/CRi subdivided by MFC-MRD assay
into MRD+ andMRD2. Patients without high-risk factors, including Flt3 internal tandem duplication
wt/2NPM1-wt subgroup, received a second daunorubicin/cytosine arabinoside induction; course 2
(C2) was intensified for patients with high-risk factors.
Results
Survival outcomes from PR and MRD+ responses after C1 were similar, particularly for good- to
standard-risk subgroups (5-year overall survival [OS], 27% RD v 46% PR v 51% MRD+ v 70%
MRD2; P , .001). Adjusted analyses confirmed significant OS differences between C1 RD versus
PR/MRD+ but not PR versus MRD+. CRi after C1 reduced OS in MRD+ (19% CRi v 45% CR; P =
.001) patients, with a smaller effect after C2. The prognostic effect of C2MFC-MRD status (relapse:
hazard ratio [HR], 1.88 [95%CI, 1.50 to 2.36], P, .001; survival: HR, 1.77 [95%CI, 1.41 to 2.22], P,
.001) remained significant when adjusting for C1 response. MRD positivity appeared less dis-
criminatory in poor-risk patients by stratified analyses. For the NPM1-wt standard-risk subgroup, C2
MRD+ was significantly associated with poorer outcomes (OS, 33% v 63% MRD2, P = .003;
relapse incidence, 89% when MRD+ $ 0.1%); transplant benefit was more apparent in patients
withMRD+ (HR, 0.72; 95%CI, 0.31 to 1.69) than thosewithMRD2 (HR, 1.68 [95%CI, 0.75 to 3.85];
P = .16 for interaction).
Conclusion
MFC-MRD can improve outcome stratification by extending the definition of partial response after
first induction and may help predict NPM1-wt standard-risk patients with poor outcome who benefit
from transplant in the first CR.
J Clin Oncol 36:1486-1497. © 2018 by American Society of Clinical Oncology
INTRODUCTION
In acute myeloid leukemia (AML), failure to
achieve morphologic complete remission (CR)
after a first cycle of induction in previously un-
treated patients is an established independent
prognostic factor from earlier studies.1-3 Thus,
morphologic response at this time point is often
incorporated with genetic and pretreatment clin-
ical parameters to guide further therapy,4 including
second induction courses, choice of consolidation,
and whether intensification from allogeneic stem-
cell transplantation (SCT) may be appropriate in
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otherwise intermediate-risk patients. Despite morphologic response
criteria being standard, a different approach for measuring response
has been proposed5,6 owing to the independent prognostic value
from measurable or minimal residual disease (MRD) assays when
discrepant with morphology,7-9 or in CR10-12 and the equivalent
poor outcomes between MRD positivity and active-disease pre-
myeloablative SCT.13,14
Studies have shown the prognostic value of MRD monitoring
by polymerase chain reaction (PCR) for patients with validated
molecular targets, usually after two courses of chemotherapy.11,12,15
Multiparametric flow cytometry MRD (MFC-MRD) may identify,
as early as after course 1 (C1), patients with a poorer response
despite achieving CR and is an assay that can be applied across AML
genetic subgroups.12,16-20 There are, however, insufficient data to as-
certain the relative prognostic effect of MFC-MRD positivity in CR
post-C1 compared with morphologic active disease; it is feasible that
the outcomes of patients with detectable MRD resemble those of
refractory patients who achieve the cytoreduction criteria for a mor-
phologic partial remission (PR).21,22 Evaluating this will help refine
which response categories are themost useful prognostic surrogate end
points to assess effectiveness of the first induction course.
It is also uncertain for patients who complete a second
chemotherapy course whether the quality of response after C1,
with inclusion of MFC-MRD assessment, adds prognostic in-
formation to CR-MRD status after course 2 (C2). The value of
MFC-MRD status to differentiate outcome at either time point is
likely to be heterogeneous between established risk subgroups due
to disease, treatment, and assay factors, but the extent of this has
not been established.
Treatment decisions, including predicting the benefit of SCT, are
particularly challenging for the standard-risk subgroup. MFC-MRD
assays are most likely to influence therapeutic choices for NPM1-wild
type (wt) patients of standard risk, following data indicating post-
induction reverse transcriptase, quantitative PCR (RT-qPCR) of
blood-mutated transcripts reliably predicts outcome for patients with
NPM1 mutation.23,24 Thus, there is a specific need to define the
usefulness of MFC-MRD for risk stratification in this subgroup.
In this study, we aimed to determine the prognostic effect of
MFC-MRD measurement incorporated into response assessment
after induction courses for the different risk subgroups, including
NPM1-wt patients at standard risk, in a large cohort of younger
patients with AML who had undergone intensive treatment in the
National Cancer Research Institute (NCRI) AML17 trial.
METHODS
Patients
Patients were enrolled in the NCRI AML17 trial (ISRCTN Registry
No. 55675535) from April 6, 2009, to December 31, 2014. A list of
treatments is provided in Appendix Fig. A1 (online only).
The AML17 protocol was designed primarily for younger patients,
generally age , 60 years. Patients with high-risk myelodysplastic syn-
drome, which was defined as . 10% marrow blasts at diagnosis, and
secondary AML were eligible. Patients with acute promyelocytic leukemia
were not included in this MRD study. After first induction, patients were
defined by risk of relapse, using a validated score comprising cytogenetics,
WBC count, age, secondary disease, morphologic response to C125,26 and
FLT-3 internal tandem duplication(ITD)/NPM1 mutation status.
Morphologic-based response criteria were as follows: (1) CR, , 5%
blasts in a cellular bone marrow with count recovery, CRi if 5% blasts but
best response was with neutropenia , 1,000/mL or thrombocytope-
nia, 100,000/mL; (2) partial remission (PR), decrease of pretreatment bone
marrow blast percentage by at least 50% to 5% to 15% in a cellular marrow
(hematologic recovery not required)1; and (3) resistant disease (RD),
. 15%marrow blasts (patients surviving at least 7 days after completion of
treatment). Responses were classified by centers.
Patients designated as favorable or at standard risk received the
second daunorubicin/cytosine arabinoside course and were then ran-
domized to receive either 1 or 2 courses of high-dose cytosine arabinoside.
High-risk patients were offered a randomization between FLAG-Ida or
daunorubicin/clofarabine with the intention of eventually proceeding to
allogeneic stem-cell transplantation (SCT). FLT3-ITD mutant patients
were directed to the lestaurtinib randomization until 2012.
The trial was sponsored by Cardiff University, approved by Wales-
REC3 and conducted in accordance with the Declaration of Helsinki.
Multiparameter Flow Cytometry Detection of MRD
Samples for multiparameter flow cytometry (MFC)-MRD were
requested at baseline (bone marrow and/or blood) and following each
course (bone marrow). A summary of sample logistics and processing is
provided in the Data Supplement. MFC-MRD analysis was performed
centrally, using standardized gating strategy that screened for “different-
from-normal” leukemia-associated-immunophenotypes (LAIPs) on blasts
pretreatment and tracked these (approximately 0.02% to 0.05% sensitivity
thresholds) but also applied the different-to-normal approach in follow-up
samples to detect changes in blast LAIPs (approximately 0.05% to 0.1%
sensitivity threshold). In this study, only samples for which there were
pretreatment LAIPs to monitor could be reported as MFC-MRD negative,
whereas samples with any level of MRD detected above a diagnostic LAIP
or different-from-normal follow-up LAIP threshold were reported as
MFC-MRD positive. Clinicians were not informed of MFC-MRD results.
Statistical Analysis
All end points were based on the revised criteria of the International
Working Group for Diagnosis.21 Survival percentages were calculated using
the Kaplan-Meier method with cumulative incidence of relapse calculated
using competing-risks methodology. Baseline characteristics were com-
pared using x2 or Mantel-Haenszel tests, with continuous variables
compared using the Wilcoxon rank-sum test. Time-to-event outcomes
were compared using log-rank tests and Cox regression. Outcomes are
reported as effect sizes with 95% confidence intervals; significance was set
at P , .05. Stratified analyses used stratified log-rank tests and are dis-
played as forest plots with tests for interaction using standard method-
ology.27 Comparison of transplantation versus not was analyzed using the
method ofMantel and Byar tomitigate immortal time bias. Median follow-
up for survival was 39.0 months (range, 1.0 to 80.5 months).
RESULTS
Induction Response by Morphology and MFC-MRD:
Patient Characteristics
Between 2009 and 2014, 6,539 samples (bone marrow [BM] or
peripheral blood at diagnosis, BM post-treatment courses) from
2,450 patients with non-acute promyelocytic leukemia recruited to
AML17 were prospectively analyzed for MFC-MRD (Appendix Fig
A2, online only). Among patients in CR post-C1, the presence of
MRD data were associated with secondary AML, and the absence of
an NPM1 mutation (reflecting the prioritizing of BM for RT-qPCR
monitoring of NPM1 mutations23 during the second phase of the
trial); survival at 5 years was 52% (with MRD data) versus 50%
jco.org © 2018 by American Society of Clinical Oncology 1487
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(withoutMRDdata). In adjusted analyses, the presence ofMRDdata
was not associated with survival (hazard ratio [HR], 0.99 [95% CI,
0.84 to 1.16]; P = .9).
Post-C1, 1,443 patients contributed data; 420 were refractory
by morphology (n = 197 RD; n = 223 PR) and 1,023 (70.9%)
achieved CR/CRi with MFC-MRD data (n = 446 MFC-MRD
negative [MRD2]; n = 577 MFC-MRD positive [MRD+]). After
C2, 806 patients were in CR/CRi with MFC-MRD data (n = 503
MRD2; n = 303 MRD+).
The clinical characteristics of patients according to response post-
C1 andMRD status for patients in CR/CRi post-C1 or C2 are listed in
Table 1. There was a significant association between responses post-C1
or C2 and cytogenetic group; however, count recovery post-C1 was
not significantly associated with MRD after either course.
Outcome Comparison for Morphologic Response and
MFC-MRD Status After C1
We evaluated overall survival (OS) by C1 response status.
Five-year OS for all enrolled in AML17 excluding early deaths was
52% for those achieving CR/CRi versus 31% for refractory patients
(P , .001). MRD status in CR/CRi versus PR or RD further dif-
ferentiated 5-year survival outcomes (Fig 1A). A PR or MRD+
response gave intermediate survival at 5 years. Survival rates
appeared equivalent between these two responses for the patients at
good or standard risk; 5-year OS for MRD2 versus MRD+ versus
PR versus RD were 63% versus 44% versus 35% versus 24%, re-
spectively, for all patients; 70% versus 51% versus 46% versus 27%,
respectively, when patients at poor risk were excluded (Fig 1B); and
66% versus 49% versus 46% versus 30%, respectively, for standard
risk alone (P , .001 for all analyses; Fig 1C). Similar results were
observed for survival censored at SCT (Fig 1D; Fig A3A, online only)
and also for NPM1-wt patients at standard risk (Fig A3B and A3C).
Adjusted analyses confirmed significant survival differences
between RD and PR/MRD+ but not between PR and MRD+ for
patients at good or standard risk (RD v PR/MRD+: OS HR, 2.28
[95% CI, 1.38 to 3.75]; P , .001; PR vs MRD+: HR, 1.32; P = .4)
and for NPM1-wt patients at standard risk (RD v PR/MRD+: OS
HR, 2.13 [95% CI, 1.21 to 3.75]; P = .008; PR vs MRD+: HR, 1.18,
P = .6). Results were similar when censored at SCT (Table 2).















CR/CRi, MRD− 446 373 272 192 122 71
CR/CRi, MRD+ 575 451 272 173 97 41
PR 197 121 72 47 31 11
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PR 59 42 28 22 15 5
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PR 42 31 22 17 12 4
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CR/CRi, MRD+ 266 165 69 45 20 9
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Fig 1. Overall survival (OS) according to response status after course 1. (A) All patients. (B) Patients at good and standard risk (patients known to be at poor risk excluded).
(C) Patients at standard risk. (D) OS for patients at standard risk censored at allogeneic stem-cell transplantation. CR, complete remission; CRi, complete remission with
absolute neutrophil count , 1,000/mL or thrombocytopenia , 100,000/mL; MRD, measurable residual disease; PR, partial remission; RD, resistant disease.
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Thus, the prognostic effect from morphologic response cri-
teria after first induction was restricted to RD in the good and
standard-risk subgroups whenMFC-MRD status was incorporated
into response assessment.
Only 25 patients were refractory by morphology post-C1 but
MRD2 (n = 22 PR; n = 3 RD) with 61% 3-year and 49% 5-year
OS. Seven of 577 MRD+ patients were in morphologic CR but
had $ 5% aberrant blasts by MFC (range, 5.4% to 38%); six died
within 2 years, with one patient alive at 58.6 months.
Relative Prognostic Effect of MFC-MRDAfter C1 and C2
by Genetic/Risk Score Subgroup
In AML17, patients received two courses of induction regardless
of remission status after C1, but C2 differed for patients designated
as poor risk by trial risk score. Analyses of survival and relapse by
MFC-MRD status of patients with disease in CR/CRi for C1 (n =
1,010) and C2 (n = 803) were performed stratified by cytogenetic28
and trial risk subgroups (Fig 2; Appendix Fig A4, online only) to
investigate the relative prognostic effect from clearance of blasts
below MFC-MRD detection threshold at either of these response
assessment time points. There was some evidence that the benefit
fromMFC-MRD negativity on OS was lower in patients at poor risk
compared with other subgroups with the NCRI AML17 treatment
schedule (P for test for trend = .01 for C1; P = .05 for C2). Overall,
MFC-MRD status appeared more prognostic for relapse and OS at
C2 (relapse: HR, 1.88 [95%CI, 1.50 to 2.36], P, .001; survival: HR,
1.77 [95% CI, 1.41 to 2.22], P , .001) than C1 (relapse: HR, 1.70
[95%CI, 1.40 to 2.06], P, .001; survival: HR, 1.50 [95%CI, 1.23 to
1.84], P , .001), although this difference diminished when C1
analysis was restricted to patients who received C2 and survived at
least 30 days post-C2 (relapse: HR, 1.80 [95% CI, 1.49 to 2.18], P,
.001; survival:, HR, 1.87 [95% CI, 1.52 to 2.29], P , .001).
Outcomes of Combined C1 Response Status and C2
MFC-MRD Status
In patients with response/MFC-MRD data for both C1 and C2
time points (n = 693), C2 MFC-MRD positivity remained significant
on OS and relapse when adjusting for C1 response (5-year survival:
HR, 1.79 [95%CI, 1.38 to 2.32], P, .001; relapse: HR, 1.52 [95%CI,
1.18 to 1.96], P= .001; Fig 3). A total of 24 patients converted fromC1
MRD2 to C2 MRD+, with a particularly poor prognosis (n = 15
relapses; n = 13 deaths); one had adverse risk cytogenetics and five had
Flt3-ITD mutations (Appendix Table A1). Patients who were MRD2
at both C1 and C2 had the best outcome (n = 224; n = 76 relapses; n =
58 deaths); of these, 80.8% were at good or standard risk and 26.3%
were NPM1-wt patients at standard risk (Appendix Table A2).
MRD Status Combined With Peripheral Count Recovery
We examined the additional prognostic effect of combining
MRD status with response by peripheral count recovery post-C1 and
C2 (Appendix Table A3). The frequencies of CRi as best response in
the total cohort were similar in MRD+ versus MRD2 patients post-
C1 (9.3% v 9.6%) and C2 (13.1% v 12.0%); CRi frequencies were
not relatively increased in theNPM1-wt standard-risk subgroup. C1
CRi was associated with significantly decreased 5-year OS for total
(39% v 53%; P= .002) and inMRD+ (19% v 45%; P= .001), but not
for MRD2 patients. MRD+ NPM1-wt patients at standard risk in
CRi also had a lower OS at 5 years (25% v 48%; P = .4), although
difference was not significant. The effect of CRi versus CR was
smaller post-C2, although outcomes were still worse in CRi/MRD+
patients. The reduced survival associated with CRi was not due to
increased relapse.
Outcome by MFC-MRD Status for NPM1-wt Patients at
Standard Risk
Because it is possible that the most appropriate MFC-MRD
cutoff level for discriminating outcome may differ among AML
genetic subgroups, we compared the 5-year cumulative incidence
of relapse for C1 MRD2 versus MRD+ , 0.1% versus MRD+
$ 0.1% by our assay in core binding factor (CBF)-AML andNPM1-
mutated as well as NPM1wt standard-risk patients. For patients
with CBF-AML and NPM1 mutation, post-C1 MRD+ at any level
(, 0.1% or $ 0.1%) significantly increased relapse (Appendix Fig
A5, online only). However, in the NPM1-wt standard-risk sub-
group, low-levelMRD+ (, 0.1%) post-C1 did not alter relapse risk
compared with MRD2 but was associated with a higher cumu-
lative incidence of relapse (CIR) when detected post-C2 (Fig 4A).
MRD+ levels of $ 0.1% detected in 35% and 13% NPM1-wt
patients at standard risk post-C1 and post-C2, respectively, pre-
dicted a high probability of relapse (C1 3-year CIR, 68%; C2 CIR,
89%). MRD status after second induction was also significantly
prognostic for survival: 33% for any level of MRD positivity versus
63% for MRD2 at 5 years (3 years, 47% v 69%; P = .003; Fig 4B).
Of the 204 NPM1-wt patients at standard risk who had C2
MRD data, 83 had an allograft (n = 44 in first CR: n = 29 MRD2
and n = 15 MRD+). When survival was censored at any SCT, rates
of 5-year OS were 35% versus 88% (3 years, 47% v 88%; P, .001;
Appendix Fig A6, online only).
We next investigated the effect of SCT in first CR according to
C2 MRD status in Mantel-Byar analyses. Although numbers were
small, results suggested that transplant might be considered in
MRD+ (HR, 0.72; 5% CI, 0.31 to 1.69) but not MRD2 patients
(HR, 1.68 [95% CI, 0.75 to 3.85]; P for interaction = .16; Fig 4C).
DISCUSSION
Response to induction therapy is a powerful prognostic indicator
in AML. There are, however, differing practices for the imple-
mentation of technologies that measure residual leukemia to assess
response. Flow cytometry is often used to support the definition of
CR by morphology; those centers with access to experienced
laboratories, including some trial groups, have extended its use to
define CR without MRD.5 It has been reported that outcomes after
myeloablative SCT for patients with pretransplant MFC-MRD
, 5% resemble those with at least 5% blasts by morphology.13
This and the similar event-free survival observed in approximately
80 pediatric patients with MRD positivity after first induction,
whether , 5% or $ 5% blasts by morphology,7 suggest that di-
chotomizing patients by a 5% blast CR cutoff fails to capture some
prognostic information. Our results confirm this. By incorporating
MFC-MRD with established response criteria of PR and RD,
distinct prognostic groups for 5-year survival emerge after the first
jco.org © 2018 by American Society of Clinical Oncology 1491
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course of standard induction. Importantly, the response subgroup
with intermediate outcome comprises patients on either side of the
current CR blast threshold, those with MRD positivity in CR and
those who are refractory but clinically classified as a PR; both
responses are associated with similar 5-year survival, particularly in
patients otherwise allocated as belonging to good- or standard-risk
subgroups. This is also the case when PR is defined by European










CBF 20/74 8/82 7.7 6.8
3.08 (1.46 to 6.52)
Intermediate 174/386 111/322 26.8 70.8 1.46 (1.16 to 1.84)
Adverse 63/87 16/27 1.8 13.5 1.14 (0.67 to 1.94)
Subtotal: 257/547 135/431 36.2 91.2
1.49 (1.21 to 1.83)
2P = .001
Test for heterogeneity between subgroups: 22 = 4.6; P = .1; NS
AML17:
2.39 (1.27 to 4.50)
1.75 (1.31 to 2.35)
1.14 (0.84 to 1.55)
Good risk 26/85 13/86 8.3 9.6
Standard risk 111/267 69/253 25.0 44.6
Poor risk 132/217 56/102 5.4 41.2
Subtotal: 269/569 138/441 38.8 95.4
1.50 (1.23 to 1.84)
2P = .001
Test for heterogeneity between subgroups: 22 = 6.2; P = .04














MRD status post course 2
Cytogenetics:
CBF 4/18 17/94 1.0 2.5
1.49 (0.44 to 5.10)
Intermediate 112/208 119/349 32.8 51.8
1.88 (1.43 to 2.47)
Adverse 43/59 17/36 6.7 14.2
1.60 (0.95 to 2.69)
Subtotal: 159/285 153/479 40.5 68.6
1.80 (1.42 to 2.29)
2P < .001
Test for heterogeneity between subgroups: 22 = 0.4; P = 0.8; NS
AML17:
Good risk 11/30 18/102 5.1 4.6
3.02 (1.22 to 7.52)
Standard risk 63/131 76/267 21.9 28.7
2.14 (1.49 to 3.09)
Poor risk 93/141 66/132 14.5 39.6
1.44 (1.06 to 1.97)
Subtotal: 167/302 160/501 41.5 73.0
1.77 (1.41 to 2.22)
2P < .001
Test for heterogeneity between subgroups: 22 = 4.0; P = .1; NS





Test for trend between subgroups: 21 = 6.2; P = .01
Test for trend between subgroups: 21 = 3.7; P = .05
Test for trend between subgroups: 21 = 0.1; P = .7; NS
Test for trend between subgroups: 21 = 4.0; P = .05
Fig 2. Forest plots for overall survival by
multiparametric flow cytometry-MRD sta-
tus for patients in complete remission. (A)
After course 1. (B) After course 2, stratified
by cytogenetic risk group and NCRI AML17
risk score group. CBF, core binding factor;
HR, hazard ratio; MRD,measurable residual
disease; NS, not significant; O-E, observed
minus expected; Var, variance.
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three post-C1 response categories could be proposed: RD, PR (MFC-
MRD+ whether below or above 5% blast threshold), and CR/CRi
without MRD. CRi was an independent risk factor to MRD in
a study that included patients with relapsed or refractory AML and
differing induction intensities.29,30 From our data, outcomes for
patients newly diagnosed with AML achieving negative MRD are
equivalent between CRi and CR after a single standard induction.
However, the relatively few patients in our cohort (4.8%) with both
CRi and MRD positivity after C1 had as poor survival (OS, 19% for
all;, 25% forNPM1-wt patients at standard risk) as patients with RD.
For those completing a second induction with a CR/CRi,
MRD status after C2 increased prognostic discrimination. Al-
though sample attrition bias may limit analyses comparing time
points, MRD negativity post-C2 improved outcome overall even
when adjusting for slower blast clearance by C1 response. This
differs from our previous results in older adults17 and might reflect
the better treatment tolerance and mutation profiles of younger
adults. However, after the second daunorubicin/cytosine arabi-
noside induction, approximately 33% of patients at standard risk
and approximately 34% of NPM1-wt patients at standard risk in
CR/CRi had persistent BM MRD by our assay. Whether detectable
MFC-MRD after completion of conventional induction is a suffi-
ciently specific prognostic surrogate to guide therapy has been
debated. The postconsolidation time point was more informative
in the GIMEMA (Gruppo Italiano Malattie Ematologiche del-
l’Adulto) study for a cohort of which approximately 70% had
intermediate cytogenetics.31,32 This suggests that in a proportion of
those with postinduction MRD positivity, consolidation may
confer a favorable outcome by additional MFC-MRD clearance
(although it is of note that for some younger adults in the
GIMEMA trials, the induction/consolidation regimen comprised
two courses in total). Genetic profile, treatment intensity, and the
later effects of any transplant may also modify interpretation and
utility of MFC-MRD to inform postremission therapy. Our data
are consistent with this because the prognostic effect as well as best
MFC-MRD cutoff level differed between AML risk groups; MRD
status appeared less discriminatory in the patients at poor risk.






MRD status in CR post course 2
HR (95% CI)
(MRD+ : MRD−)
Response status post C1:
CR MRD− 17/24 76/224 11.4 5.2
8.96 (3.79 to 21.14)
CR MRD+ 96/168 81/164 11.1 44.0
1.29 (0.96 to 1.73)
PR 18/30 10/22 3.4 6.7
1.67 (0.78 to 3.56)
RD 8/27 8/20 −1.0 3.9
0.78 (0.29 to 2.08)
Subtotal: 139/249 175/430 25.0 59.9
1.52 (1.18 to 1.96)
2P = 0·001
Test for heterogeneity between subgroups: 23 = 19.4; P = .001
Test for trend between subgroups: 21 = 7.4; P = .007











MRD status in CR post course 2
HR (95% CI)
(MRD+ : MRD−)
Response status post C1:
CR MRD− 13/24 58/224 7.5 5.1
4.34 (1.82 to 10.34)
CR MRD+ 93/169 60/166 20.0 37.9
1.69 (1.23 to 2.33)
PR 23/33 11/26 4.6 8.3
1.74 (0.88 to 3.44)
RD 14/28 9/22 1.0 5.6
1.19 (0.52 to 2.73)
Subtotal: 143/254 138/438 33.0 56.9
1.79 (1.38 to 2.32)
2P = 0·00001
Test for heterogeneity between subgroups: 23 = 5.0; P = .2; NS
Test for trend between subgroups: 21 = 2.7; P = .1; NS






Fig 3. Forest plots for (A) overall survival
and (B) relapse by combined response data
after courses 1 and 2. Effect of multi-
parametric flow cytometry-MRD status in
CR after course 2 stratified by post-C1 re-
sponse status. C1, course 1; CR, complete
remission; HR, hazard ratio; MRD, mea-
surable residual disease; NS, not signifi-
cant; O-E, observed minus expected; PR,
partial remission; RD, resistant disease;
Var, variance.
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detectable MFC-MRD at$ 0.1% early in treatment was associated
with significantly higher relapse rates (89% after C2). The false-
negative 50% CIR observed for postinduction MFC-MRD negative
patients in the NPM1-wt, standard-risk subgroup could reflect
MFC-MRD sensitivity limitations, although a similar CIR was
observed for patients with DNTM3A/NPM1 mutations who were
MRD negative by NPM1-mutated transcript RT-qPCR.23 Ex-
ploratory analyses could not identify any significant clinical pa-
rameters that predicted MRD2 relapses. Longitudinal, broad
molecular studies may disclose whether increased preleukemic
instability reinitiating AML33,34 or persistence of pretreatment
minor or major leukemic clones35,36 contributes to these false-
negative relapse risks. Notwithstanding, NPM1-wt patients at
standard risk who achieved MRD negativity post-C2 had signif-
icantly better survival rates. Because their survival rate increased to
88% when censored for transplant, there is the possibility that
transplant in first remission could be avoided in this subset. The
Mantel-Byar analysis supports this with some evidence of interaction,
although this should be interpreted cautiously because of the small
number of patients and the interaction was not significant.
Transplant decisions have mainly been arbitrary in this
subgroup, with no accepted approach to distinguish those patients
likely to be cured with chemotherapy alone (or those whose re-
sponse is likely to be successful after salvage therapy if they do
relapse) from those who benefit from transplantation in first re-
mission or potentially experimental therapy. Our results sug-
gest that allogeneic transplant in first remission could be directed
to those who are MRD+ rather than MRD2. This is the first
indication that MRD status might have utility in directing therapy
for NPM1-wt patients at standard risk despite their molecular
heterogeneity. Large patient data sets likely requiring collaborative
efforts will determine whether integrating MFC-MRD status with
genomic profiles37,38 further informs outcome prediction.
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MRD < 0.1% 57 28
MRD 0.1%+ 92 58
P = ·005
No. at risk:
MRD− 111 71 46 27 17 12
MRD < 0.1% 57 31 21 14 8 5
MRD 0.1%+ 92 47 22 11 6 0





















MRD < 0.1% 41 22
MRD 0.1%+ 27 22
P < ·00001
No. at risk:
MRD− 133 88 59 34 24 14
MRD < 0.1% 41 23 10 5 3 1
MRD 0.1%+ 27 9 3 0 0 0
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CR/CRi, MRD− 134 116 84 50 32 18







CR/CRi, MRD− 134 38







MRD status in CR post course2 
HR (95% CI)
(allograft : no allograft)
MRD− 10/29 28/134 2.9 5.6 1.68 (0.74 to 3.85)
MRD+ 5/15 29/70 −1.7 5.3 0.72 (0.31 to 1.69)
Test for heterogeneity between subgroups: 21 = 2.0; P = .2; NS






Effect 2P = .07 NS
Fig 4. Standard-risk NPM1-wild type. (A) Cumulative incidence of relapse by MRD level. (MRD2 v MRD+ , 0.1% v MRD+ $ 0.1%) after courses 1 and 2. (B) Overall
survival (OS) according to MRD status after course 2 (MRD2 vMRD+). (Not shown: MRD+$ 0.1%, OS of 24%; MRD+, 0.1%, OS of 39%). (C) Mantel-Byar analysis for
survival according to first CR stem-cell transplant by MRD after course 2. CR, complete remission; CRi, complete remission with absolute neutrophil count, 1,000/mL or
thrombocytopenia , 100,000/mL; HR, hazard ratio; MRD, measurable residual disease; NS, not significant; O-E, observed minus expected; Var, variance.
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Appendix
Supplementary Information
Multiparameter flow cytometry detection of measurable residual disease. Patients were allocated to one of three reference
multiparameter flow cytometry–measurable residual disease (MFC-MRD) laboratories, their samples were sent by overnight mail
to the allocated laboratory. Following ammonium chloride lysis, bone marrow/peripheral blood nucleated cells were labelled with
the consensus antibody panel below.
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Presentation samples were screened for leukemic-aberrant-immunophenotypes (LAIPs) and then at least tubes 1-2 from the
panel were selected for MRD analysis of follow-up samples. Bone marrow aspirates to assess remission status were performed at 18-
21 days after the end of chemotherapy. If the marrow was hypoplastic and assessment of status not possible, a repeat marrow was
performed if possible.
Each MFC-MRD laboratory used the same sample processing protocol with cell acquisition performed on a FACSCanto (BD
Biosciences, Franklin Lakes, NJ) flow cytometer (BD Biosciences). Acquisition was set for 500,000 to 1 million cells or as many cell
events as possible for follow-up samples. Data review was performed regularly to ensure interlaboratory standardization and
included periodically updated reference control bonemarrow profiles. Postacquisition analyses of the flow cytometry data from the reference
flow cytometric laboratories was performed centrally (blinded to clinical data) using FlowJo software (Treestar, Ashland, OR). LAIPs were
screened for in blast populations of presentation samples, initially CD1171 and CD341 blasts (gated by FSC/SSC/CD45/ CD117 or CD34)
with preset ‘different from normal’ regions that were also applied as a ‘different from normal’ approach in follow-up samples. LAIPs were also
screened for by overlaying CD1171 and/or CD341 leukemic blasts with reference controls (‘normal’ CD1171 and/or CD341 blasts). In
presentation samples where blasts were mainly or all negative for CD117 and CD34, blasts were gated by CD45/SSC or FSC/SSC then CD45
intermediate and other markers (such as HLADR, CD56, CD33, CD13) followed by overlaying with reference controls to identify LAIPs for
which sensitivity threshold was at least 0.05% of leukocytes (i.e. less than 0.05% of leukocytes from the control BMs fell within the defined
LAIP gate). LAIPs for monitoring in follow-up samples were selected as blast subpopulations that deviated from the normal antigen profiles
with sufficient detection sensitivity, usually comprised. 10% of leukemic blasts and from previous data (Freeman SD et al: J Clin Oncol 31:
4123-31, 2013; Bradbury C et al: Leukemia 29:988-91, 2015) were known to be stable at follow-up (~0.02-0.05% sensitivity thresholds). LAIP
percentages were reported as percentage of nucleated cells expressing the identified LAIP. In some patients minor or major immuno-
phenotypic changes from baseline LAIPs were detected by ‘different from normal’ LAIP regions. These were considered asMRD if new LAIPs
fulfilled criteria for detection sensitivity with less than 0.05% of TNCs from the control BMs fell within the newly defined LAIP gate. If no
adequate presentation samplewas available for a patient the “different-fromnormal”LAIPapproach applied to blastswas used to detectMFC-
MRD positivity. In this study only samples for which there were pre-treatment LAIPs to monitor could be reported as MRD negative whilst
samples with any level of MRD detected above a diagnostic or different-from-normal FU LAIP threshold were reported as MRD positive.
Inadequate follow-up samples (defined by, 0.1%blasts and/or, 100 cell eventswithin the total blast (gated byCD45/SSCplusCD341 and/
or CD1171) gate) were excluded from data analysis unless there was detectable MRD from a clear cluster of at least 20 LAIP cell events
detected. Any level of MFC-MRD detected above the sensitivity threshold was considered MRD-positive.
No LAIP was identified in pretreatment samples of 102 patients (5% of adequate pretreatment samples). Adequate post course
1 samples were received in 71 of these patients, 14 had detectable MFC-MRD by different from normal approach at this timepoint
(including 4 with . 5% blasts) and were included in the analysis.
Patients were designated in CR but without MRD data post course 1 or course 2 if there was 1) no / inadequate diagnostic
sample or 2) adequate diagnostic sample but no LAIP identified (unless different-from-normal LAIP identified post course 1 / 2) or
3) no / inadequate samples post course 1 / 2.
Reasons for missed samples included prioritizing of bone marrow for RT-qPCRmonitoring of NPM1mutations in the second
part of the AML17 trial.
Statistical analysis. Survival endpoints are defined as per Cheson, which indicates the time of origin for all endpoints. Survival
is calculated from entry, relapse from date of remission with death in remission as a competing risk. Follow-up was completed
March 2016. Multivariable analyses were adjusted for the known prognostic factors of age, wbc, sex, performance status, disease
type (secondary or de novo) and cytogenetic group.
AML17 MFC- MRD Antibody Panel
Tube No. FITC PE PerCP PECy7 APC APC H7 Horizon V450 Horizon V500 Brilliant Violet
1 HLADR CD13 CD34 CD117 CD33 CD45 CD19
L243 (BD) L138 (BD) 8G12 (BD) 1042D2 (BD) P67.6 (BD) 2D1 (BD) SJ25C1 (BD)
2 CD38 CD56 CD34 CD117 CD33 CD45 CD7












4 CLL1 (CLEC12A, BD) CD123
7G3(BD)
CD34 CD117 CD19 SJ25C1 (BD) CD45RA CD45 CD38
NOTE. Pre-treatment samples –Tubes 1-3,4; Follow-up samples – at least Tubes 1-2,4.Tube 4was applied as 1) to screen for CD123 aberrant profile on CD341/CD1171
cells, 2) an R&D ‘LSC’ tube (CLL1/CD45RA LSC results not reported as MRD in this study).
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Fig A1. Flowchart of treatments given to patients in the NCRI AML17 trial. (A) Pre-October 2011 (induction gemtuzumab ozogamicin randomization). (B) Post-October
2011 (daunorubicin dose randomization in induction). Note: patients who did not satisfy the hepatic entry criteria (liver function, 23 ULN) in (A) were allocated ADE; until
June, 2010 the consolidation randomizationwasMACE vsMACE/MidAC; the DA dose randomizationwas closed in October, 2013, and patients subsequently received DA
(60 mg); the lestaurtinib (CEP-701) randomization closed in October 2012; the mTOR (everolimus) randomization closed in August, 2012; the high risk randomization in
October, 2012. All core binding factor (CBF) leukemias were eligible for gemtuzumab ozogamicin and were given 3 mg/m2 with course 2 if they did not receive it by
gemtuzumab ozogamicin randomization with course 1. From June, 2012 patients with informative real-time quantitative polymerase chain reaction (RT-qPCR) MRD
markers could enter the ‘Monitor vs noMonitor’ randomization that investigates the impact of serial RT-qPCRmonitoring post completion of treatment on outcome, quality
of life and health economics. ADE, cytarabine, daunorubicin, and etoposide; APL, acute promyelocytic leukemia; CBF, core binding factor; CEP-701, lestaurtinib; DA,
daunorubicin and cytarabine; GO, gemtuzumab ozogamicin (3 or 6 mg/m2); FLAG-Ida, fludarabine, cytarabine, GCSF, and idarubicin; FLT3, FMS-like tyrosine kinase-3;
mTOR, everolimus; R, randomization.
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Patients in study
(N = 2,450)
Patients with C1 and C2 data
(n = 693)











Excluded from C2 MRD analysis







































Excluded from C1 response analysis
Dead by day 30
No response data*












Fig A2. CONSORT diagram. Outline of patient sample flow for MRD study. (*) Includes patients for whom remission status could not be classified as exact timing of any
remission was unavailable. CR, complete remission; C1, course 1, C2, course 2. LAIP, leukemia-associated–immunophenotype; MRD, measurable residual disease.
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Time Since Entry (years)
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CR/CRi, MRD− 111 96 67 44 25 16
CR/CRi, MRD+ 149 125 76 46 24 11
PR 27 20 14 11 7 2





CR/CRi, MRD− 111 32

















CR/CRi, MRD− 111 16
CR/CRi, MRD+ 149 36
PR 27 6
RD 34 14














CR/CRi, MRD− 70 42 23 12 9
CR/CRi, MRD+ 94 29 19 8 3
PR 8 5 4 3 2






Time Since Entry (years)
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CR/CRi, MRD− 446 277 176 114 71 43
CR/CRi, MRD+ 575 304 131 74 39 16
PR 197 43 22 14 10 6


















Fig A3. OS according to response status after course 1. (A) All patients. OS censored at allogeneic SCT. (B) NPM1–wild-type patients at standard risk. (C) NPM1–wild-
type patients at standard risk, censored at allogeneic SCT. CR, complete remission; MRD, measurable residual disease; OS, overall survival; PR, partial remission; RD,
resistant disease; SCT, stem-cell transplantation.
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A
Relapses/Patients Statistics
MRD status post course 1
HR (95% CI)
(MRD+ : MRD−)
2.89 (1.70 to 4.90)
1.43 (1.15 to 1.79)
1.99 (1.05 to 3.75)
Subtotal:
1.62 (1.34 to 1.97)
2P < .001
Test for heterogeneity between subgroups: 22 = 6.1;  = .05
Test for trend between subgroups: 21 = 1.5;  = .2; NS
2.23 (1.37 to 3.63)
1.79 (1.39 to 2.32)
1.32 (0.93 to 1.89)
Subtotal:
1.70 (1.40 to 2.06)
2P < .001
Test for heterogeneity between subgroups: 22 = 3.3;  = .2; NS
Test for trend between subgroups: 21 = 3.2;  = .07
















































0.0 0.5 1.0 1.5 2.0
Relapses/Patients Statistics
MRD status post course 2
HR (95% CI)
(MRD+ : MRD−)
1.29 (0.56 to 2.98)
1.86 (1.44 to 2.42)
1.63 (0.89 to 2.98)
Subtotal:
1.78 (1.41 to 2.24)
2P < .001
Test for heterogeneity between subgroups: 22 = 0.8;  = .7; NS
Test for trend between subgroups: 21 = 0.0;  = .8; NS
1.70 (0.88 to 3.30)














































1.88 (1.50 to 2.36)
2P < .001
Test for heterogeneity between subgroups: 22 = 2.1;  = .4; NS






Fig A4. Forest plots for relapse by multiparametric flow cytometry-MRD status for patients in CR (A) after course 1 and (B) after course 2 stratified by cytogenetic risk
group and NCRI AML 17 risk score group. CR, complete remission; MRD, measurable residual disease.
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Time After CR (years)
No. at risk:
MRD− 67 55 42 30 23 16
MRD 0.1%+ 27 17 13 6 25

































Time After CR (years)
No. at risk:
MRD− 125 100 66 51 28 14
MRD < 0.1% 56 32 19 10
MRD 0.1%+ 43 25 15 12 69
14
B
Fig A5. Cumulative incidence of relapse by multiparametric flow cytometry -MRD level. (MRD2 v MRD+ , 0.1% v MRD+ $ 0.1%) after course 1. (A) CBF AML. (B)
Standard-risk NPM1 mutant. AML, acute myeloid leukemia; CBF, core binding factor; MRD, measurable residual disease; MRD , 0.1%, MRD+ , 0.1%; MRD 0.1%+,
MRD+ $ 0.1%.























CR/CRi, MRD− 86 46 29 20 12134
CR/CRi, MRD+ 41 11 4 1 170
88%
35%
Fig A6. Standard-risk NPM1-wild type. Overall survival (OS) according to mul-
tiparametric flow cytometry-MRD status after course 2, censored at any allogeneic
stem-cell transplantation. CR, complete remission; MRD, measurable residual
disease.
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CR/CRi, MRD− 253 170 110 70 43 24
CR/CRi, MRD+ 267 165 69 45 20 9
37 14 10 8 6 3
RD 41 7 4 1 1 1
Time Since Entry (years)

































CR/CRi, MRD− 344 306 225 161 104 62
CR/CRi, MRD+ 358 300 190 120 69 32
48 37 24 20 13 4
RD 65 33 20 7 5 3






























Time Since Entry (years)
PR
No. at risk:
CR/CRi, MRD− 253 221 160 114 69 41
CR/CRi, MRD+ 267 219 133 91 49 22
37 29 19 15 10 3
RD 41 23 16 5 3 2































446 373 272 192 122 71
575 451 272 173 97 41




RD 281 136 73 40 21 12













































Fig A7. OS according to response status after course 1, applying European LeukemiaNet (ELN)/Cheson criteria for PR and RD instead ofMRC criteria (ELN criteria for PR:
all hematologic criteria of CR; decrease of bone marrow blast percentage to 5% to 25% with decrease of pretreatment bone marrow blast percentage by$ 50%). (A) All
patients. (B) Patients at good and standard risk (patients known to be at poor risk excluded). (C) Patients at standard risk. (D) Patients at standard risk, OS censored at
allogeneic SCT. CR, complete remission; MRD, measurable residual disease; OS, overall survival; PR, partial remission; RD, resistant disease; SCT, stem-cell
transplantation.
jco.org © 2018 by American Society of Clinical Oncology
MFC-MRD and Response Criteria in AML Risk Groups
Downloaded from ascopubs.org by 31.54.63.64 on May 17, 2021 from 031.054.063.064
Copyright © 2021 American Society of Clinical Oncology. All rights reserved. 
Table A1. Genetic Characteristics of C1 MFC-MRD- / C2 MFC-MRD+ Patients
Karyotype Cytogenetic Risk Group NPM1 Mutation Flt3 ITD
46,XY,t(8;21)(q22;q22)[7]/47,idem,+8[3] Good Negative Negative
46,XY[20] Intermediate NA NA
46,XY[20] Intermediate Positive Positive
46,XY[20] Intermediate Positive Positive
46,XX[16] Intermediate Positive Positive
46,XX[20] Intermediate Negative Positive
46,XY[20] Intermediate Negative Positive
46,XX[20] Intermediate Positive Negative
46,XY[20] Intermediate Negative Negative
46,XX[20] Intermediate Negative Negative
46,XX[20] Intermediate Negative Negative
46,XX[20] Intermediate Negative Negative
46,XX,t(11;19)(q23;p13.1)[10] Intermediate Negative Negative
46,XY,del(9)(q?2q?3)[9]/46,XY[2] Intermediate Negative Negative
46,XX,t(2;9)(p22;p21)[12]/46,XX[1] Intermediate Negative Negative
46,XY,t(6;9)(p23;q24)[9]/46,XY[1] Intermediate Negative Negative
46,XY[20] Intermediate Negative Negative
45,XX,dic(17;18)(p11.2;p11.2)[9]/46,XX[1] Intermediate Negative Negative
46,XX[20] Intermediate Negative Negative
46,XY[20] Intermediate Negative Negative
47,XY,+8[6]/ 46,XY[4] Intermediate Negative Negative
50,XY,+X,+4,t(10;11)(p12;q14),+15,+19[9]/ 46,XY[1] Adverse Negative Negative
Failed NA Negative Negative
Failed NA Negative Negative
Abbreviations: ITD, internal tandem duplication; NA, not applicable.


















All (patients with both
C1 and C2 data)
693 224 (32.3) 24 (3.5) 166 (24.0) 170 (24.5) 26 (3.8) 33 (4.8) 22 (3.2) 28 (4.0)
Post-C1 risk score
Good 110 (15.9) 48 (21.4) 2 (8.3) 34 (20.5) 19 (11.2) 2 (7.7) 3 (9.1) 1 (4.5) 1 (3.6)
Standard 347 (50.1) 133 (59.4) 15 (62.5) 87 (52.4) 87 (51.2) 12 (46.2) 4 (12.1) 6 (27.3) 3 (10.7)
Poor risk 234 (33.4) 41 (18.3) 7 (29.2) 45 (27.1) 64 (37.6) 12 (46.2) 26 (78.8) 15 (68.2) 24 (85.7)
Not assessable 2 (0.3) 2 (0.9) 0 0 0 0 0 0 0
NPM1wtstandard risk 180 (26) 59 (26.3) 10 (41.2) 50 (30.1) 43 (25.3) 8 (30.8) 4 (12.1) 6 (27.3) 3 (10.7)
Post-C1 response
CR (excluding CRi) 538 (77.6) 202 (90.2) 23 (95.8) 157 (94.6) 156 (91.8)
CRi 46 (6.6) 22 (9.8) 1 (4.2) 9 (5.4) 14 (14.4)
NOTE: Data given as No. (%) unless otherwise indicated.
Abbreviations: C1, course 1; C2, course 2; CR, complete remission; CRi, complete remission with absolute neutrophil count , 1,000/mL or thrombocytopenia
, 100,000/mL; MRD, measurable residual disease; RD, resistant disease (, 50% reduction in blast numbers with. 15% residual blasts); PR, partial response ($ 50%
reduction in blast numbers with 5% to 15% residual blasts); wt, wild type.
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Table A3. Outcomes for Patients by Peripheral Count Recovery Response Combined With MRD Status
MRD status No. (%CRi) 5-Year (3-year) OS P 5-Year (3-year) CIR P
All patients
Post-C1
CR v CRi 933/88 (9.4) 53 v 39 (60 v 46) .002 50 v 43 (46 v 40) .6
MRD- CR v MRD- CRi 407/39 (9.6) 63 v 63 (70 v 63) .2 40 v 33 (35 v 33) .7
MRD+ CR v MRD+ CRi 528/9 (9.3) 45 v 19 (52 v 33) .001 58 v 53 (54 v 47) .6
Post-C2
CR v CRi 716/89 (12.4) 54 v 38 (59 v 46) .02 51 v 47 (48 v 44) .9
MRD- CR v MRD- CRi 449/54 (12.0) 63 v 52 (68 v 52) .05 61 v 57 (59 v 57) .9
MRD+ CR v MRD+ CRi 267/35 (13.1) 37 v 20 (46 v 40) .3 45 v 40 (41 v 36) .9
Standard risk NPM1 wt
Post-C1
CR v CRi 241/19 (7.9) 52 v 42 (64 v 56) .16 58 v 66 (53 v 66) .2
MRD- CR v MRD- CRi 100/11 (11.0) 60 v 64 (77 v 64) .2 49 v 66 (41 v 66) .07
MRD+ CR v MRD+ CRi 141/8 (5.7) 48 v 25 (55 v 50) .4 65 v 69 (61 v 69) .8
Post-C2
CR v CRi 180/24 (13.3) 54 v 47 (63 v 47) .3 58 v 43 (55 v 43) .6
MRD- CR v MRD- CRi 118/16 (13.6) 63 v 61 (70 v 61) .6 52 v 34 (48 v 34) .5
MRD+ CR v MRD+ CRi 62/8 (12.9) 35 v 23 (50 v 23) .10 70 v 67 (70 v 67) .7
Abbreviations: C1, course 1; C2, course 2; CIR, cumulative incidence of relapse; CR, complete remission; CRi, complete remission with absolute neutrophil count
, 1,000/mL or thrombocytopenia , 100,000/mL; MRD, measurable residual disease; NPM1, nucleophosmin. OS, overall survival; wt, wild type.
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